HonCode

Go Back   HER2 Support Group Forums > her2group
Register Gallery FAQ Members List Calendar Today's Posts

Reply
 
Thread Tools Display Modes
Old 02-19-2007, 06:49 PM   #1
eric
Senior Member
 
Join Date: Sep 2005
Posts: 589
Taxotere and JMR-132

http://news.yahoo.com/s/afp/20070130...ushealthcancer

Combination therapy promising for breast cancer: Study

CHICAGO (AFP) - An experimental new treatment for breast cancer can dramatically shrink, and in some cases, eliminate, tumors in mice that have been infected with the disease, a study has said. <SCRIPT language=javascript>if(window.yzq_d==null)window.y zq_d=new Object();window.yzq_d['ipGHBdGDJHQ-']='&U=13b5fr6u1%2fN%3dipGHBdGDJHQ-%2fC%3d571699.10029817.10887929.1442997%2fD%3dLREC %2fB%3d4368327';</SCRIPT><NOSCRIPT></NOSCRIPT>
The new therapy involves a combination of a chemotherapy drug, Taxotere (generic name: docetaxel) and a novel compound called JMR-132, that starves the tumor of growth-stimulating hormone. The compound binds to receptors on the tumor, and in so doing blocks the release of the growth hormone.

Tested separately, the drug and the growth factor inhibitor were extremely effective at shrinking the tumors in mice infected with a hard-to-treat, estrogen-independent form of breast cancer.

On its own, the Taxotere reduced the volume of the mice tumors by an average of 74 percent in three weeks. In mice treated with JMR-132, the volume reduction was 63 percent.

Together, the two therapies reduced the volume of the cancerous cells by more than 97 percent. In some cases, when the researchers examined the dead mice, they could not find any cancer cells at all.

What's more, the treatment did not appear to be toxic or trigger any other major side effects in the animals, suggesting it might be well-tolerated in humans, the researchers said.
eric is offline   Reply With Quote
Old 02-19-2007, 09:21 PM   #2
heblaj01
Senior Member
 
Join Date: Apr 2006
Posts: 543
Thanks Eric for this post which covers the new JMR-132 drug. It is likely to be developed past mice experiments since "Tulane University has applied for a patent on the GHRH antagonist JMR-132" . This makes it attractive to potential licencees among pharmaceutical companies.

I am not sure about the stated inocuity of the Docetaxel dosage since in mice experiments they used it intraperitonally while in humans it is given as an I.V.
I don't know how to correlate the dose of 20mg/kg in mice with the 75 to 100mg per square meter in humans.
However the 10 µg/day (sub cutanous) looks very small & hopefully less toxic in humans than Docetaxel.
heblaj01 is offline   Reply With Quote
Reply


Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 02:58 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter